{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:59:51Z","timestamp":1780775991904,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["305,507"],"award-info":[{"award-number":["305,507"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["IMI2-CARDIATEAM"],"award-info":[{"award-number":["IMI2-CARDIATEAM"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101115416"],"award-info":[{"award-number":["101115416"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018703","name":"HORIZON EUROPE European Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijcha.2026.101906","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:17:44Z","timestamp":1774930664000},"page":"101906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of sodium-glucose cotransporter inhibitors in hypertrophic cardiomyopathy: a systematic review"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7717-8568","authenticated-orcid":false,"given":"Lorenzo","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6992-4641","authenticated-orcid":false,"given":"Luisalice","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7968","authenticated-orcid":false,"given":"Taras","family":"Chendey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6578-2379","authenticated-orcid":false,"given":"Sravani","family":"Modumudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2950-9058","authenticated-orcid":false,"given":"Andrea","family":"Minghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-1298","authenticated-orcid":false,"given":"Job A.J.","family":"Verdonschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-7803","authenticated-orcid":false,"given":"Stephane R.B.","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2026.101906_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120878","article-title":"Hypertrophic cardiomyopathy: an overview of genetics and management","volume":"9","author":"Teekakirikul","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijcha.2026.101906_b0010","first-page":"E533","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2026.101906_b0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2459\/JCM.0000000000001616","article-title":"Management of hypertrophic cardiomyopathy","volume":"25","author":"Zhang","year":"2024","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.ijcha.2026.101906_b0020","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/jamacardio.2021.0689","article-title":"Prevalence of hypertrophic cardiomyopathy in the UK biobank population","volume":"6","author":"Lopes","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.acvd.2022.06.003","article-title":"Medical treatment of patients with hypertrophic cardiomyopathy: an overview of current and emerging therapy","volume":"115","author":"Iavarone","year":"2022","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcha.2026.101906_b0030","first-page":"800","article-title":"The revolution of cardiac myosin inhibitors in patients with hypertrophic cardiomyopathy","volume":"40","author":"Haraf","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjcard.2023.10.059","article-title":"The efficacy of cardiac myosin inhibitors versus placebo in patients with symptomatic hypertrophic cardiomyopathy: a meta-analysis and systematic review","volume":"210","author":"Yassen","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0040","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0045","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2026.101906_b0050","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group*. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine 2023;388:117\u201327. DOI: 10.1056\/NEJMoa2204233.","DOI":"10.1056\/NEJMoa2204233"},{"key":"10.1016\/j.ijcha.2026.101906_b0055","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0060","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2026.101906_b0065","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijcha.2026.101906_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ijcha.2026.101906_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwad322","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study","author":"Jung","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100843","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy","volume":"3","author":"Aglan","year":"2024","journal-title":"JACC Advances"},{"key":"10.1016\/j.ijcha.2026.101906_b0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.amjcard.2022.10.054","article-title":"Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy","volume":"188","author":"Subramanian","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2026.101906_b0095","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2026.101906_b0100","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2026.101906_b0105","doi-asserted-by":"crossref","unstructured":"Bhatt MS, Pitt B Christopher, Cannon CP, Leiter LA, McGuire DK, Lewis JB, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056\/NEJMoa2030186.","DOI":"10.1056\/NEJMoa2030186"},{"key":"10.1016\/j.ijcha.2026.101906_b0110","article-title":"Association between the 2022 AHA\/ACC\/HFSA heart failure staging and cardiovascular and kidney outcomes in patients with diabetes and kidney disease: a post hoc analysis of the SCORED randomized controlled trial","volume":"22","author":"Odutayo","year":"2026","journal-title":"Circ. Heart Fail."},{"issue":"4","key":"10.1016\/j.ijcha.2026.101906_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ijcha.2026.101906_b0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcha.2026.101906_b0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cvr\/cvae004","article-title":"Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors","volume":"120","author":"Wijnker","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcha.2026.101906_b0130","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf324","article-title":"Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model","author":"Baka","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2026.101906_b0135","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2026.101906_b0140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2026.101906_b0145","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2026.101906_b0150","unstructured":"A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy (SONATA-HCM). Https:\/\/WwwClinicaltrialsGov\/Study\/NCT06481891?Tab=table#recruitment-Information n.d."},{"key":"10.1016\/j.ijcha.2026.101906_b0155","unstructured":"University of Pennsylvania. Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy (SOTA-CROSS HCM). Https:\/\/ClinicaltrialsGov\/Study\/NCT06433050?Intr=Sotagliflozin&viewType=Table&rank=4 n.d."},{"key":"10.1016\/j.ijcha.2026.101906_b0160","unstructured":"Yonsei University. ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy. Https:\/\/ClinicaltrialsGov\/Study\/NCT06580717 n.d."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906726000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906726000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:23:56Z","timestamp":1780773836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906726000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S2352906726000400"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2026.101906","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of sodium-glucose cotransporter inhibitors in hypertrophic cardiomyopathy: a systematic review","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2026.101906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101906"}}